This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Teva Women’s Health, Inc. To Present New Data At The 68th Annual Meeting Of The American Society For Reproductive Medicine

Teva Women’s Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), today announced new reproductive health data that will be featured at the 68 th Annual Meeting of the American Society for Reproductive Medicine (ASRM). The meeting, held in San Diego October 20-24, 2012, features three company-sponsored posters, one of which will be an oral presentation.

“Our heritage in research and development of women’s health products has resulted in innovative potential offerings that address several aspects of reproduction, including contraception and in vitro fertilization,” Nancy Ricciotti, senior director of clinical affairs, Teva Women's Health R&D. “Additionally, we are dedicated to using our experience to educate and empower women to take control of their reproductive health.”

Featured presentations include:

  • Data from the Phase III clinical trial of Milprosa™ (progesterone), an investigational once-weekly progesterone vaginal ring for luteal supplementation in women undergoing in vitro fertilization
  • Efficacy and safety results from the Phase III clinical trial of Quartette™ (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets), an investigational ascending-dose extended-regimen oral contraceptive that is currently under review by the U.S. Food & Drug Administration

Platform Presentation/Poster Session Details:

Milprosa™

  • [O-14] Impact of Luteal Supplementation with a Weekly Progesterone Vaginal Ring During In Vitro Fertilization (IVF) by Day of Embryo Transfer (ET) (Oral Session: Clinical Female Infertility and Gynecology: Monday, October 22, 2012: 6:00 – 6:15 p.m. PDT) Mark Perloe, MD, Atlanta; Herman Weiss, MD, Israel; and Brandon Howard, PhD, Frazer, Pa.
  • [P-263] Satisfaction with Progesterone Vaginal Ring (PGN VR): Survey of Women Participating in a Randomized Trial of Weekly PGN VR vs. 8% PGN Gel as Luteal Support After In Vitro Fertilization (IVF) (Poster Session: Luteal Phase Support: Tuesday, October 23, 2012 from 7:00 – 9:00 a.m.) Kaylen M. Silverberg, MD, Austin, Texas and Brandon Howard, PhD, Frazer, Pa.

Quartette™

  • [P-285] Multicenter Open-Label Study to Evaluate Efficacy and Safety of an Ascending-Dose, Extended-Regimen Ethinyl Estradiol/Levonorgestrel Combination Oral Contraception for Preventing of Pregnancy in Women (Poster Session: Contraception/Family Planning: Tuesday, October 23, 2012 from 7:00 a.m. to 9:00 a.m.) David J. Portman, MD, Columbus, Ohio; Brandon Howard, PhD, Frazer, Pa.; Herman Weiss, MD, Israel; Andrew M. Kaunitz, MD, FACOG, Jacksonville, Fla.; and Nancy Ricciotti, MSN, North Wales, Pa.

About Milprosa™

Teva’s investigational once-weekly progesterone vaginal ring, Milprosa™, is a flexible transvaginal ring that is designed to continuously release a steady dose of progesterone in development for luteal phase support for women undergoing in-vitro fertilization.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs